This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
Horio M, Imai E, Yasuda Y, et al. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32–8.
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.
Muto S, Kawano H, Higashihara E, The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015;19:867–77.
The authors’ appreciate Tadashi Okada and Kazumasa Kishi (Otsuka Pharmaceutical Co., Ltd.) for the discussion on the statistical works.
Conflict of interest
The authors have received honoraria for presentations and research funding from and have consulted and been advisory board members for Otsuka Pharmaceutical.
About this article
Cite this article
Horie, S., Muto, S. In Reply to “The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease”. Clin Exp Nephrol 20, 149–150 (2016). https://doi.org/10.1007/s10157-015-1154-7